Published finding — does the expert body still believe it?
Evolocumab significantly reduced the key secondary composite endpoint of cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.73–0.88) compared with placebo in ASCVD patients receiving background statin therapy.
TL;DR · AI-generated
In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Author-implied confidence
94%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
98% → 98% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
· openalex W2596179513 · s2 993698dd
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0322
Evolocumab added to statin therapy significantly reduced the composite primary endpoint of cardiovascular death, MI, stroke, unstable angina hospitalization, or coronary revascularization (HR 0.85; 95% CI 0.79–0.92) in ASCVD patients over a median 2.2-year follow-up.
0.1018
Alirocumab added to high-intensity statin therapy reduces the composite risk of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina hospitalization compared to placebo in patients with recent acute coronary syndrome (HR 0.85; 95% CI 0.78–0.93).
0.1206
In patients with atherosclerotic cardiovascular disease on statin therapy, evolocumab reduced LDL cholesterol by 59% at 48 weeks, from a median of 92 mg/dL to 30 mg/dL, compared with placebo.
0.1279
Alirocumab treatment is associated with a numerically lower all-cause mortality rate compared to placebo in post-ACS patients on high-intensity statins (3.5% vs. 4.1%; HR 0.85; 95% CI 0.73–0.98).
0.1513
Icosapent ethyl 4 g daily reduces the key secondary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% (HR 0.74) compared to placebo in statin-treated patients with elevated triglycerides.
0.1565
Patients with atherosclerotic cardiovascular disease whose baseline LDL cholesterol is in the lowest quartile (median ~74 mg/dL) still derive cardiovascular benefit from further LDL lowering with evolocumab.